Fatty acid synthase (FAS; EC 2.3.1.85) was purified to near homogeneity from a human hepatoma cell line, HepG2. The HepG2 FAS has a specific activity of 600 nmol of NADPH oxidized per min per mg, which is about half that of chicken liver FAS. All the partial activities of human FAS are comparable to those of other animal FASs, except for the 13-ketoacyl synthase, whose significantly lower activity is attributable to the low 4'-phosphopantetheine content of HepG2 FAS. We cloned the human brain FAS cDNA. The synthesis of long-chain fatty acids from acetyl-CoA, malonyl-CoA, and NADPH is a complex process catalyzed by the fatty acid synthase (FAS). In animal tissues, the active synthase is a homodimer of a multifunctional protein that is organized in a head-to-tail fashion, generating two active catalytic centers (1). The seven partial activities and the site for the prosthetic group, 4'-phosphopantetheine (acyl carrier protein), are arranged on the multifunctional protein subunit from the amino to carboxyl termini in the following order: f3-ketoacyl synthase, acetyl-CoA and malonyl-CoA transacylases, dehydratase, enoyl reductase, ketoacyl reductase, acyl carrier protein, and thioesterase (1). Most information about the synthase is derived from nonhuman animal studies, so little is known about the human synthase. Investigators who isolated the enzyme from human biopsy tissues (2-5) or cell lines (6) have shown that, except for the enzyme from the SKBR3 cell line (6), all the human FAS preparations had lower activity than the FASs of other animals. This lower activity of the human FAS is comparable to the activities of related human enzymes that are involved in lipogenesis (e.g., pyruvate dehydrogenase, citrate lyase, and glucose-6-phosphate dehydrogenase), which are lower (by a factor of 4-7) in human tissues than in other animal tissues, implying that lipogenesis in humans is highly repressed (7-9).
apparently does not contribute to the lower activity of HepG2
FAS.
The synthesis of long-chain fatty acids from acetyl-CoA, malonyl-CoA, and NADPH is a complex process catalyzed by the fatty acid synthase (FAS). In animal tissues, the active synthase is a homodimer of a multifunctional protein that is organized in a head-to-tail fashion, generating two active catalytic centers (1) . The seven partial activities and the site for the prosthetic group, 4'-phosphopantetheine (acyl carrier protein), are arranged on the multifunctional protein subunit from the amino to carboxyl termini in the following order: f3-ketoacyl synthase, acetyl-CoA and malonyl-CoA transacylases, dehydratase, enoyl reductase, ketoacyl reductase, acyl carrier protein, and thioesterase (1) .
Most information about the synthase is derived from nonhuman animal studies, so little is known about the human synthase. Investigators who isolated the enzyme from human biopsy tissues (2) (3) (4) (5) or cell lines (6) have shown that, except for the enzyme from the SKBR3 cell line (6) , all the human FAS preparations had lower activity than the FASs of other animals. This lower activity of the human FAS is comparable to the activities of related human enzymes that are involved in lipogenesis (e.g., pyruvate dehydrogenase, citrate lyase, and glucose-6-phosphate dehydrogenase), which are lower (by a factor of [4] [5] [6] [7] in human tissues than in other animal tissues, implying that lipogenesis in humans is highly repressed (7) (8) (9) .
Here we describe the purification and catalytic properties of human FAS from HepG2 human hepatoma cells and report how the relatively low specific activity of the enzyme results from the low 4'-phosphopantetheine content of the protein.
We also report the cloning and sequence analyses of the human FAS cDNA. §
MATERIALS AND METHODS
Materials. All the reagents and chemicals were purchased from Sigma, except for [1-14C] acetyl-CoA and [2-14C] malonylCoA (Amersham), triacetic acid lactone (4-hydroxy-6-methyl-2-pyrone; Aldrich) N-acetyl-S-acetoacetylcysteamine (Research Plus, Bayonne, NJ), DNA-modifying enzymes (New England Biolabs), dideoxy sequencing kits (United States Biochemical), and radiochemicals from (DuPont/NEN). Chromatography columns (FPLC, Superose-6 HR 10/30) and all other chromatographic equipment were purchased from Pharmacia. Human brain and liver poly(A)+ RNA and a multiple human tissue Northem blot were obtained from Clontech.
Assays of FAS and Its Partial Activities. The synthase activity was assayed by measuring the rate of oxidation of NADPH or the incorporation of radiolabeled acetyl-CoA or malonyl-CoA into palmitate (10) . The partial activities of FAS were assayed as described earlier: the acetyl/malonyl transacylases (11), dehydratase (12), ,B-ketoacyl synthase (12), f3-ketoacyl reductase (13) , ,B-hydroxyacyl enoyl reductase (12) , and thioesterase (14) . The f3-ketoacyl synthase activity was also determined by measuring the increase in absorbance at 280 nm due to formation of triacetic acid lactone (15) . 4 '-Phosphopantetheine Content. To determine the 4'-phosphopantetheine content of FAS, we developed a simple and sensitive method based on spectrophotometric measurement of the phenylthiocarbamoyl (PTC) derivative of taurine released after performic acid oxidation and hydrolysis of the protein. PTC-taurine can be separated from other PTC-amino acids by using reverse-phase high-performance liquid chromatography (HPLC) and following the absorbance at 254 nm. In this system, the PTC derivatives of cysteic acid and taurine are eluted close to each other. The molar ratio of cysteic acid to taurine was determined and used to normalize the peak heights based on the known amino acid compositions of the chicken and human FASs. In a typical analysis, 10-20 jig of human or chicken FAS, after being dialyzed against distilled water and lyophilized, was treated with performic acid (0.2 ml) at room temperature for 2 hr. The oxidized FAS was lyophilized and hydrolyzed in 200 ,ul of 6 M HCI at 110°C for 24 hr. The acid was removed by repeated lyophilization, and the amino acid hydrolysate was treated with 20 ,ul of a phenyl isothiocyanate solution (ethanol/water/triethylamine/phenyl isothiocyanate, 7:1:2:1, vol/vol). After incubation at 37°C for 1 hr, the PTC products were dried in vacuum, and the residue was dissolved in the isocratic elution buffer (aqueous 0.1% formic acid/0.4% acetic acid) and analyzed on a Rainin Microsorb C18 column (0.46 cm x 10 cm; particle size, 3 ,um; pore size, 100 A). A standard mixture of taurine and cysteic acid (1:40, based on their relative presence in the FAS subunit) was treated with phenyl isothiocyanate as described above and separated by reverse-phase HPLC under the same experimental conditions. The values obtained were used to normalize the recovery of 4'-phosphopantetheine.
Cloning of Human FAS cDNA. The human brain FAS cDNA clone EST01325 (16) (19, 20) and isolated clone C-30. By using primers based on the sequences of Try 3-27 [bases 559-576 (17)] and C-30 (bases 2434-2451), we isolated clone C-27B. We also used primers based on a genomic clone, clone A (data not shown), which contained the first three exons of human FAS and a reverse primer from C-27B (bases 1198-1212), and obtained clone C-10. The PCR products were isolated, made blunt ended, and cloned into the Sma I site of Bluescript vector (21) .
Miscellaneous Procedures. The FASs of chicken (22) and rat (23) liver were isolated as described. Previously described procedures were used for protein determination (24) , SDS/ PAGE analysis (25) , and DNA sequencing, Northern blotting, random primer labeling, and isolation of plasmid DNA (21) . The fatty acids were analyzed as methyl esters on a Varian 3500 gas/liquid chromatograph equipped with a DB-225 capillary column (0.25 mm x 30 m).
RESULTS AND DISCUSSION
Purification and Properties of Human FAS. The human hepatoma cell line HepG2 was grown to confluency in fifty 2-liter roller bottles containing Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. The cells were collected, harvested, and washed three times with 500 ml of cold phosphate-buffered saline (50 mM potassium phosphate, pH 7.4/150 mM NaCl). The cell pellet (100 g) was suspended in 300 ml of buffer A [50 mM Tris HCl, pH 8.0/1 mM EDTA/5 mM dithiothreitol/10% (vol/vol) glycerol containing the protease inhibitors leupeptin, antitrypsin, and aprotinin, each at 5 ,ug/ml] and was disrupted in a PotterElvehjem homogenizer with a tight-fitting pestle. The cell lysate was centrifuged for 30 min at 30,000 x g, and the supernatant was fractionated with ammonium sulfate. The protein fraction that precipitated between 25% and 40% saturation was collected, dialyzed against buffer B (50 mM potassium phosphate, pH 7.4/1 mM EDTA/5 mM dithiothreitol/5% glycerol), and fractionated on a DEAE-Bio-Gel column (Bio-Rad; bed volume, 100 ml) by first washing the column with 300 ml of buffer B and by following with a gradient of 0-0.2 M NaCl in 300 ml of buffer B. The active protein was isolated after precipitation with ammonium sulfate at 40% saturation, dissolved in 10 ml of buffer B, dialyzed against buffer B, and loaded onto a Sephacryl S-300 column (Pharmacia; bed volume, 150 ml; size, 2 cm x 80 cm). The synthase was eluted with buffer B, precipitated with ammonium sulfate, dissolved in buffer A, and fractionated on a Superose 6 column. The active enzyme was eluted with buffer A, precipitated with ammonium sulfate, redissolved in buffer A, and stored at -80°C. This procedure yielded 1.5 mg of highly purified FAS (600 nmol of NADPH oxidized per min per mg of protein) with an overall yield of 31%. Although a similar procedure was followed to prepare the FAS from HeLa cells, the yield and the specific activity (300 nmol of NADPH oxidized per min per mg of protein) were very low.
The FAS preparations were homogeneous as judged by SDS/PAGE, with an estimated subunit molecular weight of 265,000, which is comparable to that of the rat and chicken enzymes ( Fig. 1) . Human FAS had an optimal pH value of 6.5 to 6.7 for fatty acid synthesis, and the apparent Km values were 8 ,uM for acetyl-CoA, 20 ,uM for malonyl-CoA, and 25 ,uM for NADPH. The specificity of human FAS for the acyl primer is similar to that of rat liver FAS (26) but differs from that of chicken liver FAS in that it prefers butyryl-CoA (Km = 4 ,uM) over acetyl-CoA. In addition, the fatty acids synthesized by the human FAS, like those of the rat synthase, are primarily palmitate (90%) with small amounts of myristate (4%) and stearate (6%), whereas the products of synthesis by the chicken FAS (26) are palmitate (60-70%) with larger amounts of stearate (15-20%) and myristate (5%). Acetoacetyl-CoA can substitute for acetyl-CoA as a primer of fatty acid synthesis catalyzed by human FAS without a lag in NADPH oxidation (data not shown), suggesting that the conversion of the acetoacetyl group into a butyryl group by the ,B-ketoacyl reductase, P-hydroxyacyl dehydratase, and enoyl reductase partial activities in FAS proceeds efficiently to provide a primer for fatty acid synthesis without intermission. The ability of human FAS to use acetoacetyl-CoA as a primer in fatty acid synthesis may be physiologically significant since it provides a way to consume acetoacetyl-CoA and shorter chain fatty acids in the synthesis of long-chain fatty acids.
The overall human FAS activity, whether measured by NADPH oxidation or by incorporation of radiolabeled acetylCoA or malonyl-CoA into fatty acids, was about one-third that of the chicken enzyme (Table 1) . However, most partial activities were nearly equal to those of the chicken enzyme, except for the 8-hydroxyacyl dehydratase and enoyl reductase, which were 3.2 and 20.8 times higher in the human synthase than in the chicken FAS (Table 1) . On the other hand, the partial activity of the 3-ketoacyl synthase was about one-third that of the chicken enzyme. To verify the values obtained for the activity of the 3-ketoacyl synthase, the partial activity was assayed by two independent methods: (i) the incorporation of (27) has been reported, little is known about how FAS activity is regulated posttranslationally. Since the prosthetic group is indispensable for fatty acid synthesis and its turnover rate is more rapid than that of FAS protein, at least in rat tissues (28) (29) (30) , Roncari (3) has proposed that the turnover of 4'-phosphopantetheine is an efficient mode for regulating FAS activity. The loss of 4'-phosphopantetheine from HepG2 FAS suggests that such a mechanism may be operative in the HepG2 cell line.
Characterization of Human FAS cDNA. As described under Materials and Methods, we have isolated four overlapping cDNA clones: C-10, C-27B, C-30, and B27-2. These clones and the cDNA clone EST01325 (16) cover the entire coding region of the human brain FAS (Fig. 2A) . The sequence of the rat FAS primer used in the PCR cloning of C-30 was determined by the sequence of the overlapping clone C-27B (Fig. 2) . The sequence of the primer used from the HepG2 cDNA clone, Try3-27 (17), was found to be the same in the brain tissue, on the basis of the sequence of clone C-10. The cDNA sequence was partially confirmed by sequencing subclones of the human FAS genomic DNA clone 43D6 (17) . The restriction map of this genomic DNA clone identified several restriction sites in common with the cDNA sequence. Using these restriction sites, we generated subclones GHFAS22, GHFAS24, GHFAS8, GH-FAS2, and GHFAS1 (Fig. 2B ) and determined the sequence from both ends of these fragments. The exonic sequences of the genomic DNA clones had 100% identity with the corresponding cDNA sequences. Sequencing of clone GHFAS22 revealed that it contained only the 5' flanking sequence and not the FAS coding sequence. We also located the translation initiation codon (ATG) and the termination codon (TAG) in the sequences of genomic DNA clones GHFAS24 and GHFAS1, respectively. Based on the locations of the start and stop codons in the restriction map (Fig. 2B) , we calculated that a genomic DNA sequence of -19 kb contains the 7512-bp coding sequence of human FAS. Schweizer et al. (31) reported that rat FAS is encoded by 15-16 kb of genomic DNA. In contrast, the entire goose FAS gene spans "50 kb (32) .
Analysis of the Human FAS Sequence. The nucleotide sequence of human brain FAS cDNA has an open reading frame of 7512 nt coding for 2504 amino acids (Fig. 3A) . The molecular weight of the protein is calculated to be 272,516, which is close to the estimated molecular weight of 265,000 for HepG2 FAS (Fig. 1) . The amino acid sequence shows about 79% and 63% identity, respectively, with the amino acid sequences of the rat and chicken FASs. We readily identified the highly conserved active sites of the acetyl/malonyl transacylases, the 3-ketoacyl synthase, and the thioesterase (17) . The locations of the ATG translational start codon and the TAG translational stop codon are shown in parentheses. The genomic DNA subclones GHFAS22, GHFAS24, GHFAS8, GHFAS2, and GHFAS1, which were partially sequenced, are shown. The BamHI and Kpn I restriction sites that are common to both the cDNA Fig. 3A) . The catalytically important sequence motif at the active sites of the various partial activities are conserved (Fig. 1A) . Previous work has shown that the catalytic mechanism of the thioesterase may be similar to that of serine proteases and lipases, which employ a serine-histidine-aspartic acid catalytic triad as part of their catalytic mechanism (14, 34) , and that the His274 of the chicken FAS thioesterase domain is essential for its activity (34) . In addition, mutating the aspartic residue next to His237 caused partial loss (40%) of rat mammary gland thioesterase II (14) . In agreement with these findings, the human brain FAS cDNA sequence also has these histidine (Wis2475) and aspartic (Asp2474) residues (Fig. 34) in the corresponding positions in the sequences.
A consensus sequence for the active site of the 13-hydroxyacyl dehydratase was reported as His878 ... Gly882 ... Pro887 (35) . Mutagenesis of His878 to Ala resulted in the loss of j3-hydroxyacyl dehydratase partial activity. In human FAS (Fig. 3A) , we from the human breast carcinoma cell line ZR-75-1. These sequences were found in our human brain FAS amino acid sequences (residues 753-758 and 1285-1297, respectively). In our sequence, however, the E and X in the second peptide were replaced with G and D, respectively (Fig. 3A) . Sequence analysis of the genomic clone GHFAS8 also confirmed the presence of glycine at this position. The discrepancy between our results and the published peptide sequence may be due to an error in peptide sequencing or to the characteristics of ZR-75-1 cells (see below).
Initially, we cloned C-20, a human FAS cDNA, by using HepG2 total RNA ( Fig. 2A) and primers based on the rat FAS cDNA sequence (nt 2417-2436) and human brain cDNA EST01325 (nt 3946-3964). Beginning with nt 3576 in Fig. 3 , the nucleotide sequence of C-20 is colinear with that of brain FAS, except for a 53-bp sequence (nt 3892-3944). The deduced amino acid sequence (positions 1297-1315) also differs in this region (Fig. 3B) genomic cDNA clones or in brain and liver cDNA clones, is unique to HepG2. Since this discrepancy occurs within an exon, this variation is not a result of alternative splicing. Whether the differences represent true polymorphism is yet to be determined.
There is only 15% sequence homology between HepG2 and brain sequences in the region coding for the interdomain of FAS domains I and II (Fig. 3A) . Apparently, the variant 53-bp sequence lies in the interdomain region, which can accommodate mutations and may not be functionally important. Hence, the lower activity of HepG2 FAS is unlikely to be related to this sequence variation. In addition, the FAS activities from various tissue samples (2) (3) (4) (5) and other cultured cells (33) already indicate that human FAS activity is lower than the activities of the rat and chicken FASs. Whether the lower FAS activity in the human enzyme is due to regulation of pantethenylation is yet to be established.
Finally, in humans there is only one species of FAS mRNA (9.3 kb in size) in the various tissues we tested (Fig. 4) . In addition, our results demonstrate that FAS expression is high in brain, pulmonary, and hepatic tissues, which is consistent with the idea that these organs are the major sites of de novo fatty acid biosynthesis.
